AMP
This study demonstrates that Harbinger’s cfDNA methylation assay delivers robust analytical and clinical performance across a two-tier reflex workflow that combines cost-efficient screening with highly specific confirmation and tissue localization. This scalable and reliable MCED approach is well suited for population-based testing and enables earlier detection of high-mortality cancers.
